NCT00797589 is a Phase 4 clinical trial of HES in Valve Surgery, sponsored by University of Helsinki.

Who is sponsoring NCT00797589?

NCT00797589 is sponsored by University of Helsinki.

What drugs are being tested in NCT00797589?

Interventions in NCT00797589: HES, Ringer lactate.

What condition does NCT00797589 study?

NCT00797589 studies Valve Surgery, Coronary Artery Bypass Grafting.

Is NCT00797589 still recruiting?

NCT00797589 is currently completed. Last updated 24 August 2015.

Last reviewed 2015-08-24 · How we verify

NCT00797589

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Prime Solution on Fluid Balance After Open Heart Surgery

Completed Phase 4 Last updated 24 August 2015

What this trial tests

Phase 4 trial testing HES in Valve Surgery in 35 participants. Completed in 1 September 2012.

Timeline

1 January 2009

Primary endpoint
1 September 2012

1 September 2012

Quick facts

Lead sponsor	University of Helsinki
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	35
Start date	1 January 2009
Primary completion	1 September 2012
Estimated completion	1 September 2012
Sites	1 location across Finland

Drugs / interventions tested

HES — full drug profile →
Ringer lactate

Conditions studied

Valve Surgery — all drugs for Valve Surgery →
Coronary Artery Bypass Grafting — all drugs for Coronary Artery Bypass Grafting →

Sponsor

University of Helsinki

Who can join

18 and older, any sex, with Valve Surgery or Coronary Artery Bypass Grafting. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

fluid balance
Time frame: 1 postoperative day

Sponsor's own description

The use of Tetraspan® as prime solution can reduce fluid extravasation after perfusion versus Ringer acetate. Plasma-adapted HES-solutions produce also less acidosis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Valve Surgery

Currently open trials in the same condition.

NCT06602336 — A Single Centre Study Comparing Continuous Interstitial Fluid Lactate Detection to Standard Measurements of Lactate in P · NA · recruiting

Other University of Helsinki trials

Trials by the same sponsor.

NCT07212361 — Infant Microbiota Restoration With Maternal Microbes · NA · recruiting
NCT06799988 — NutFinForce: The Impact of Digitally Delivered Lifestyle Performance Medicine Intervention on Defense Performance in Fin · not yet recruiting
NCT06464003 — Orthodontic Screening in Public Healthcare · recruiting
NCT06092372 — The Role of Genetics in Weight Loss · NA · completed
NCT06564675 — Accuracy of EEG Slow Wave Activity in Predicting Favourable Outcome in Patients With Hypoxic Brain Injury - A Substudy o · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00797589 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Helsinki
Last refreshed: 24 August 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00797589.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing